Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus
NCT06475586 on ClinicalTrials.gov · last registry update 2024-07-01
A small phase 4 — 30 participants, against a typical 75. The sponsor logged completion for 1 March 2024. Primary outcome, as filed: clinical characteristics of patients with psoriasis. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- University of Banja Luka
- Sponsor type
- Other
- Enrollment
- 30
- Started
- 2023-05-03
- Primary completion
- 2024-03-01 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
clinical characteristics of patients with psoriasis
Conditions studied
Psoriasis Vulgaris · Diabetes Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.